Navigation Links
VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
Date:12/14/2010

glycemic control and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

About Obesity

Obesity is a chronic condition defined by having excess body fat. Obesity significantly increases the risk of developing many different diseases and health conditions, including type 2 diabetes, hypertension, metabolic syndrome, cardiovascular disease, some cancers and osteoarthritis. According to a report in The Lancet in 2009, morbid obesity shortens life expectancy by approximately 10 years, and moderate obesity shortens it by approximately 3 years.

Approximately one-third of American adults (more than 72 million people) are obese, and many more are overweight with co-morbidities. Beyond its impact on health, obesity accounts for 9.1% of US annual health care spending – nearly $150 billion.

About VIVUS

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US regulators. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' cur
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VIVUS to Present at Two Upcoming Investor Conferences
2. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
3. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
4. VIVUS Announces Sale of MUSE Assets to Meda
5. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. VIVUS to Present at Lazard Capital Markets Healthcare Conference
8. VIVUS Announces Promotion of Peter Tam to President
9. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
10. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
11. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015   Mallinckrodt plc (NYSE: MNK ), ... 13, 2015, at the Bank of America Merrill Lynch 2015 ... Las Vegas, Nev. ... Officer, and Cole Lannum , Senior Vice President of ... in a session scheduled to begin at 3 p.m. Eastern ...
(Date:5/4/2015)... Colo., May 4, 2015  Array BioPharma Inc. ... the third quarter of its fiscal year ending ... Executive Officer of Array, noted, "With the close of ... and encorafenib, two innovative oncology products in Phase ... product in 2016. These transformative transactions have accelerated ...
(Date:5/4/2015)... HAVEN, Conn. , May 4, 2015 /PRNewswire/ ... chosen by the American Optometric Association (AOA) to ... delivery and outcomes for the millions of patients ... Measures and Outcomes Registry for Eyecare (MORE) ... will securely facilitate efficient secondary uses of essential ...
Breaking Medicine Technology:Mallinckrodt To Present At Bank Of America Merrill Lynch 2015 Health Care Conference 2Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 10American Optometric Association, Prometheus Research to Create Transformative Health Outcomes Registry 2
(Date:5/4/2015)... DC (PRWEB) May 04, 2015 ... has just released the first-ever congenital heart ... Cardiac Catheterization Laboratory (PCCL) accreditation. Driven by ... standards are a comprehensive review of interventional ... congenital heart disease. , “The ACE CHD ...
(Date:5/4/2015)... Sara Soulati, CEO of Global Cardio ... Los Angeles associated with the field of Enhanced External ... Sara Soulati Health For Life Program (SSHFLP). , The ... modification and disease prevention program. A provisional patent ... Patents and Trademarks Office and is now under review ...
(Date:5/3/2015)... ANGELES, American Telemedicine Association 2015 Meeting & Tradeshow ... e-health solutions, a full-service telemedicine and mobile health ... new platform, VITA health services for chronic disease ... services platform enables remote patient monitoring of a ... heart failure (CHF), diabetes, COPD, hypertension and other ...
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch ... latest and coolest technology products available to consumers. Scott Steinberg, ... review and shared with viewers how to protect their private ... is on computers and even more so online. It helps ... all over the world. In terms of work, the internet ...
(Date:5/3/2015)... It is not too late to register to take part ... Lissa Anne Been in Arnold, Missouri on May 9, 2015. ... honor her loving memory. It has benefited the renowned Brain Aneurysm ... 37, Lissa suffered a brain aneurysm . After two operations ... event is designed to serve as a remembrance of her and ...
Breaking Medicine News(10 mins):Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2
... not invincible but its weaknesses can be difficult to detect. ... Greek warrior whose one vulnerability led to his undoing ... weak spots. In their largest and most comprehensive effort to ... and the Dana-Farber Cancer Institute examined cells from over 100 ...
... University College of Engineering student, has received the 2011 ... program financially supports scientific studies that investigate and aim ... a Ph.D. student under the supervision of Sean Wu, ... is developing an innovative, 3-D computer-aided diagnostic system to ...
... CITY One-fifth of all patients with pulmonary arterial ... two years before being correctly diagnosed and properly treated, ... at Intermountain Medical Center in Salt Lake City. ... is more difficult and the damage is irreversible," said ...
... stroke Stroke is a leading cause of long-term ... researchers led by Gregory Bix, at Texas A&M College ... exploit one of the brain,s self-repair mechanisms to protect nerve ... The authors suggest that this approach could provide a nontoxic ...
... changes in the structure of DNA so-called epigenetic ... cells, according to one of two studies conducted by ... Cancer Institute. Together with collaborators from a biotechnology company, ... that blocks these changes could deactivate cancer-promoting genes and ...
... are physically active and eat plenty of vegetables but few ... study led by researchers at the Keck School of Medicine ... published in the July 2011 issue of the American ... to examine how weight among Chinese adolescents relates to factors ...
Cached Medicine News:Health News:Project Achilles pinpoints vulnerabilities in ovarian cancer 2Health News:Project Achilles pinpoints vulnerabilities in ovarian cancer 3Health News:New study may lead to quicker diagnosis, improved treatment for fatal lung disease 2Health News:JCI online early table of contents: July 11, 2011 2Health News:JCI online early table of contents: July 11, 2011 3Health News:JCI online early table of contents: July 11, 2011 4Health News:JCI online early table of contents: July 11, 2011 5Health News:JCI online early table of contents: July 11, 2011 6Health News:JCI online early table of contents: July 11, 2011 7Health News:JCI online early table of contents: July 11, 2011 8Health News:Epigenetic pathway and new drug show promise in reversing a hard-to-treat childhood cancer 2Health News:Epigenetic pathway and new drug show promise in reversing a hard-to-treat childhood cancer 3Health News:'Healthy' habits linked to childhood obesity in China 2Health News:'Healthy' habits linked to childhood obesity in China 3
... The next generation Powerheart AED has ... our flagship, feature-rich AED offering. The ... new customer-friendly features such as more ... new lighter weight, redesigned form factor, ...
... Plus™ is the best EMR value for ... in mind, Charting Plus™ relies heavily on ... features to improve documentation quality and increase ... content is specific to your medical specialty. ...
... the vast information needs of orthopedics specialty. ... for common orthopedics complaints, history of present ... also includes orthopedics specific ICD and CPT ... charges and quickly generate electronic Superbill at ...
... Maximo, Model 7303, incorporates new advances in CRT ... Proven Marquis ICD Platform. With this device, ... in 9 seconds or less throughout the life ... (14% increase in longevity over InSync II Marquis) ...
Medicine Products: